Introduction: Acute myocardial infarction is the leading cause of death & a person having an acute myocardial infarction usually has sudden chest pain, shortness of breath, sweating, nausea, vomiting, abnormal heartbeats, and anxiety, but it may be asymptomatic. (1) The main ways for diagnosis are ECGs and blood tests a CK-MB and troponin. Soluble Human Suppression of Tumorigenicity 2 (ST2) is a novel biomarker in inflammatory conditions and cardiovascular disease, and it plays a role in ventricular remodeling and heart failure (HF) progression. In patients with HF, ST2 is strongly associated with both disease severity and mortality.

Aim of study: To study the role of serum level of ST2 in ST elevation myocardial infarction, and its relation to clinical outcome and mortality.

Methods: Samples were collected from 60 patients who developed ST segment elevation myocardial infarction, patients were followed up during ICU stay till discharge and then were evaluated after one month for the detection of CHF, Recurrent MI, ( by history taking and Echocardiography), or death.
Results: In our study we found that there was a highly significant relationship between ST2 and the development of CHF and death with P value < 0.05 and 0.001 respectively, Also we found a significant relationship between ST2 level and need of vasopressors and MV with P value < 0.05. Clinical follow up after 30 days show a significant relationship between ST2 and the development of CHF & death after 30 days with P value 0.001, 0.01 respectively. In Echocardiography we found that there was a highly significant relationship between ST2 and EF, LVED and LVES with P value